Lab21 gets first Chinese approval for syphilis assay
This article was originally published in Clinica
Executive Summary
An assay used in syphilis screening developed by UK firm Lab21 has been approved in China. The assay detects Treponema pallidum haemagglutination (TPHA). The Chinese market for in vitro diagnostics is worth around $1.5bn and is expanding by 15% annually, according to Lab21. "Our TPHA assay is already the leading syphilis assay in a number of key blood screening markets and we are delighted to make it available in another key region," the Cambridge-based company said.